NCT05602207 - Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 25, 2022

Primary Completion Date

December 3, 2024

Study Completion Date

January 9, 2025

Conditions

Atopic Dermatitis

Interventions

DRUG

Abrocitinib

100 mg Abrocitinib once daily (QD) for 12 weeks

Trial Locations (12)

Inno-6050 Site 21, Miami Lakes

Inno-6050 Site 19, St. Petersburg

Inno-6050 Site 22, Birmingham

Inno-6050 Site 17, Auburn Hills

Inno-6050 Site 13, Fountain Valley

Inno-6050 Site 16, Quincy

Inno-6050 Site 15, Winnipeg

Inno-6050 Site 18, Newmarket

Inno-6050 Site 11, Toronto

Inno-6050 Site 10, Montreal

Inno-6050 Site 14, Québec

Inno-6050 Site 20, Québec